Monday, January 30, 2023
wellness India Expo
Home Tags Revenue

Tag: Revenue

Hester’s consolidated profit stands at Rs. 6.94 crore in Q2 FY23

The company has garnered the revenue of Rs. 77.60 crores during the period ended September 30, 2022

Glamyo Health targets USD 100 million ARR in 2022-23

The healthcare startup has reached a mark of 400 surgical centers across 26,000 pin codes, adding at least 50-60 centers on an average every quarter

Glenmark Pharma reports revenue growth of 13.9%

For the third quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs. 31,734 Mn as against Rs. 27,868 Mn recording an increase of 13.9% YoY.

Syngene reports 10% revenue growth from operations

For the nine months to December 31 2021, the company delivered growth of 21% in revenue from operations to Rs.18,461 Mn. A highlight for the quarter was the extension of our long-standing collaboration with Amgen Inc until 2026

Novozymes embarks on mission to double its revenue by 2030

Unveiling its 2025-strategy, Novozymes sets out an organic sales growth target of 5+% CAGR for the 5-year period until 2025, coupled with the ambition to double the company’s revenue by 2030.......................

Venus Remedies rides high on exports, registers 61% growth in sales...

The company’s annual sales grew from Rs 339.33 crore in FY 2019-20 to Rs 548.12 crore this fiscal, a 61% growth over last year. It posted a net profit of Rs 61.77 crore in FY 2020-21........................

Syngene clocks 12% growth in FY21 revenue at Rs. 2,184 crore

Underlying revenue from operations (excluding export incentives) for the quarter grew 13% compared with the same period last year and by 12% for the full year......................

Max Healthcare reports strong growth in Q3

Company's gross revenue stood at INR 1160 Cr, a growth of 6% YoY and 24% QoQ.....................

Zydus Cadila’s net profit up by 41% in Q3 FY21

While the company's consolidated revenues for the quarter at Rs. 3,796 Crore, up 4% Y-o-Y, the consolidated net sales for the quarter at Rs 3754 crore up by 6% Y-o-Y....................

Jubilant Life Sciences YoY revenue up by 21% at 9,111 crore

While the company recorded the year on year revenue growth up to 21 percent standing ar Rs 9,111 crore and EBITDA up by 14% to Rs 1,775 crore. The normalized PAT stood at Rs 855 crore. During the fourth quarter, revenue was Rs 2,386 crore and normalized PAT was at Rs 135 Crore................